Cargando…
Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group
BACKGROUND: Sequential anthracyclines and taxanes are standard adjuvant chemotherapy for patients with high-risk axillary node-positive breast cancer. We compared a sequential to a concurrent regimen in high-risk node-negative early breast cancer. METHODS: Patients were eligible if they had tumours...
Autores principales: | Mavroudis, Dimitrios, Saloustros, Emmanouil, Boukovinas, Ioannis, Papakotoulas, Pavlos, Kakolyris, Stylianos, Ziras, Nikolaos, Christophylakis, Charalampos, Kentepozidis, Nikolaos, Fountzilas, Georgios, Rigas, Georgios, Varthalitis, Ioannis, Kalbakis, Konstantinos, Agelaki, Sofia, Hatzidaki, Dora, Georgoulias, Vasilios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584474/ https://www.ncbi.nlm.nih.gov/pubmed/28641315 http://dx.doi.org/10.1038/bjc.2017.158 |
Ejemplares similares
-
Front-Line Bevacizumab plus Chemotherapy with or without Maintenance Therapy for Metastatic Breast Cancer: An Observational Study by the Hellenic Oncology Research Group
por: Kokkali, Stefania, et al.
Publicado: (2022) -
Nab-paclitaxel as second-line treatment in advanced gastric cancer: a multicenter phase II study of the Hellenic Oncology Research Group
por: Katsaounis, Panagiotis, et al.
Publicado: (2018) -
Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
por: Vamvakas, Lambros, et al.
Publicado: (2014) -
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group
por: Koinis, F, et al.
Publicado: (2017) -
Panitumumab in combination with modified docetaxel/cisplatin/5-fluorouracil as first-line treatment in gastric and gastroesophageal junction adenocarcinomas: a multicenter phase II study by the Hellenic Oncology Research Group
por: Kentepozidis, Nikolaos, et al.
Publicado: (2018)